Hepatocellular Carcinoma
📧 Sign up to get email alerts when something new happens for Hepatocellular Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2019-06-04Clinical Trial Update: Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma [Phase 2, Phase 3]
A clinical trial comparing liposomal doxorubicin plus gemcitabine to oxaliplatin plus fluorouracil/leucovorin for hepatocellular carcinoma h…
-
CLINICAL_TRIALS withdrawal · 2019-06-04Clinical Trial Update: Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma [Phase 2, Phase 3]
Phase 2/3 trial comparing Gemcitabine plus Oxaliplatin to Oxaliplatin plus Fluorouracil/Leucovorin for hepatocellular carcinoma has been wit…
-
CLINICAL_TRIALS withdrawal · 2019-06-04Clinical Trial Update: Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma [Phase 2, Phase 3]
A clinical trial comparing systemic chemotherapy to transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma has been wi…
-
CLINICAL_TRIALS withdrawal · 2019-06-04Clinical Trial Update: Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma [Phase 2, Phase 3]
A clinical trial comparing adjuvant transcatheter arterial chemoembolization to adjuvant systemic chemotherapy for hepatocellular carcinoma …
-
CLINICAL_TRIALS withdrawal · 2019-05-02Clinical Trial Update: Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria [Phase 3]
Phase 3 trial comparing lenvatinib plus PD-1 antibody versus TACE for intermediate-stage hepatocellular carcinoma beyond Up-to-seven criteri…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2019-05-02Clinical Trial Update: Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC [Phase 3]
A Phase 3 trial comparing lenvatinib plus a PD-1 antibody versus lenvatinib alone for hepatocellular carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-06-25Clinical Trial Update: Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for the Treatment of Localized Hepatocellular Carcinoma [NA]
A randomized trial comparing stereotactic body radiation therapy and microwave ablation for localized hepatocellular carcinoma has been with…
-
CLINICAL_TRIALS withdrawal · 2018-06-15Clinical Trial Update: Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) [Phase 2]
This clinical trial update reports the withdrawal of a Phase 2 study examining sequential partial liver transplantation followed by bone mar…
-
CLINICAL_TRIALS withdrawal · 2018-04-19Clinical Trial Update: Combination Treatment for Advanced Liver Cancer [Phase 3]
A Phase 3 clinical trial evaluating a combination therapy for advanced hepatocellular carcinoma, including cases with hepatic portal vein tu…
-
CLINICAL_TRIALS withdrawal · 2018-02-26Clinical Trial Update: Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis [NA]
Clinical trial NCT01710293, sponsored by the VA Office of Research and Development, has been withdrawn. The study evaluated an intervention …
-
CLINICAL_TRIALS withdrawal · 2017-11-17Clinical Trial Update: Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis. [NA]
A clinical trial comparing non-selective beta blockers to endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleedi…
-
CLINICAL_TRIALS withdrawal · 2017-08-31Clinical Trial Update: Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma [NA]
A clinical trial comparing Lipiodol/ethiodized oil with drug-eluting beads for hepatocellular carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-08-16Clinical Trial Update: GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start
The GIDEON trial's non-Nexavar arm for hepatocellular carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-08-07Clinical Trial Update: DAA in the Risk of Recurrence After Curative Treatment of HCC [Phase 4]
Phase 4 clinical trial evaluating direct-acting antivirals for reducing recurrence after curative treatment of hepatocellular carcinoma was …
-
CLINICAL_TRIALS withdrawal · 2017-06-26Clinical Trial Update: Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery [Phase 2]
A Phase 2 trial evaluating radiolabeled glass beads (TheraSphere) for unresectable primary liver cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-05-05Clinical Trial Update: Direct Peritoneal Resuscitation Plus Conventional Resuscitation [Phase 4]
The Phase 4 clinical trial NCT01882218 evaluating Direct Peritoneal Resuscitation plus Conventional Resuscitation for hepatocellular carcino…
-
CLINICAL_TRIALS withdrawal · 2017-05-02Clinical Trial Update: Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]
A Phase 1b/2 trial of oprozomib in combination with sorafenib for advanced hepatocellular carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-04-28Clinical Trial Update: A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma
A Phase III trial for post-operative HBV-related hepatocellular carcinoma was terminated; no efficacy results are reported in this update.
-
CLINICAL_TRIALS withdrawal · 2017-04-25Clinical Trial Update: Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) [Phase 1, Phase 2]
This trial update reports that the Tocilizumab study in patients with Hepatocellular Carcinoma undergoing transarterial chemoembolization ha…
-
CLINICAL_TRIALS withdrawal · 2017-04-13Clinical Trial Update: Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients
A clinical trial investigating the role of hepatocyte SLAMF3 receptor and MDR proteins in sorafenib resistance in hepatocellular carcinoma p…
-
CLINICAL_TRIALS withdrawal · 2017-03-30Clinical Trial Update: Resveratrol and Human Hepatocyte Function in Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial of resveratrol for hepatocyte function in liver cancer was withdrawn. The sponsor was the University of Louisvill…
-
CLINICAL_TRIALS withdrawal · 2017-01-31Clinical Trial Update: A Study to See if we Can Predict How Your Liver Tumor or Liver Metastases Will Respond to Trans-Arterial Embolization (TAE)
A clinical trial evaluating whether factors can predict how liver tumors or liver metastases respond to trans-arterial embolization has been…
-
CLINICAL_TRIALS withdrawal · 2016-11-15Clinical Trial Update: Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating temsirolimus in combination with sorafenib for advanced hepatocellular carcinoma was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-09-01Clinical Trial Update: Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma [Phase 2]
Novartis-sponsored Phase 2 trial of INC280 (capmatinib) for advanced hepatocellular carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-06-08Clinical Trial Update: Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation [NA]
A clinical trial investigating body composition in hepatocellular carcinoma patients treated with radioablation has been withdrawn.